Fig. 7

In vivo biocompatibility of NCG. A The blood routine parameters in different treated mice groups (n = 3). white blood cells (WBC), neutrophils ratio (NEUT%), lymphocyte ratio (LYM%), monocyte ratio (MONO%), red blood cells (RBC), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean platelet volume (MPV), and hemoglobin (Hb). Data are presented as mean ± SD, *p < 0.05 compared to the Control group. B The changes of urea, creatinine (Cr), and uric acid (UA) in different treated mice group (n = 3); C the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total protein (TP), albumin (ALB), globulin (GLB), alkaline phosphatase (ALP) levels in different treated mice groups (n = 3). Data are presented as mean ± SD, *p < 0.05 compared to the Control group; ^#p < 0.05 indicates a comparison between the two groups. D Coagulation function in mice across various treatment groups (n = 3). Prothrombin time (PT), prothrombin time ratio (PT%), fibrinogen (FIB), active partial thromboplastin time (APTT), thrombin time (TT). Data are presented as mean ± SD, *p < 0.05 compared to the Control group. E Representative pathological images of major organs in mice from different treatment groups. Scar bar: 50 μm. F Representative pathological images of uterine sections and endometrial thickness statistics for mice in distinct treatment groups (scar bar: 0.5 mm), and representative micro-CT images (scar bar: 1 mm) of femurs in mice from various treatment groups, accompanied by bone density, trabecular bone number, and trabecular separation statistics (G) (n = 3). Data are presented as mean ± SD, ***p < 0.001 compared to the Control group